84results about How to "Sensitive diagnosis" patented technology

A homogeneously illuminating ophthalmic instrument includes an illumination device having a source of illumination, a homogenizing unit and a projection device, at least one organic or inorganic source of radiation with spectrally selective emission being used as a source of illumination. The illumination generated in this way enables correspondingly adapted visual and / or digital observation, recording or display of the examined regions of the eye by a visualizing unit.

The invention relates to a transformer winding deformation fault diagnosis method based on frequency sweep short circuit characteristics. The transformer winding deformation fault diagnosis method comprises the following steps: 1) measuring frequency sweep short circuit impedance data of a transformer three-phase winding through a testing device under the power failure state of a transformer; 2) obtaining three diversity factor curves of the frequency sweep short circuit impedance data of the three-phase winding measured in step 1); 3) comparing three diversity factor curves DAB, DBC and DCA calculated from step 2) with standard diversity factor curves, diagnosing that the winding has slightly deformation when any one diversity factor curve exceeds attention value curves of the standard diversity factor curves; otherwise diagnosing that the winding has no deformation; and if the diversity factor curves exceed alarm value curves of the standard diversity factor curves, diagnosing that the winding has obvious deformation. The transformer winding deformation fault diagnosis method is accurate and sensitive to diagnose, easy to implement, and strong in field maneuverability and can be widely applied to fault diagnosis of transformer winding.

The invention discloses application of MYOZ1 in diagnosing and treating parkinsonism, belonging to the technical field of new application of genes. The experiment proves that the MYOZ1 gene expression in the blood of a parkinsonism patient is enhanced as compared with a normal person, which indicates that the MYOZ1 expression level in the blood can be detected to diagnose whether a subject suffers from parkinsonism. The in-vitro MTT experiment detect that the MYOZ1 gene expression is not beneficial to growth of human neuroblastoma cells. Therefore, the MYOZ1 has favorable development and application prospects in preparing products for diagnosing and treating parkinsonism.

The invention discloses a DSG3 gene as a molecular marker for early diagnosis of acute myocardial infarction. By utilization of a gene chip and a QPCR method, the situation is discovered that expressions of the DSG3 gene in blood of normal persons and patients with acute myocardial infarction show significant difference, and whether a subject suffers from acute myocardial infarction can be determined through detection of the expression situation of the DSG3 gene in blood. A kit for diagnosis of acute myocardial infarction is developed according to correlation. Diagnosis of acute myocardial infarction is carried out through detection of expression of the DSG3 by utilization of the kit. The diagnostic kit can be used for early diagnosis of diseases, and has wide application prospects in clinic.

The invention relates to a tumor-specific targeting polypeptide and an application thereof. Particularly, the amino acid sequence of the tumor-specific targeting polypeptide is shown in SEQ ID No.2. The polypeptide provided by the invention is connected with a polyamide-amine dendritic high molecular nano material and then can be well combined with various tumor cells in vitro and has a wide application in diagnostic imaging and targeted therapy of tumors as a target agent.

The invention relates to a polypeptide capable of specific tumor-binding. The amino acid sequence of the polypeptide is shown as SEQ ID No.1. According to the invention, phages specifically binding with lung cancer are obtained by means of a phage display in vivo screening method to determine sequence in order to synthesize the specific binding polypeptide. The polypeptide can achieve excellent in vitro binding with a plurality of tumor cells subsequent to the conjunction with poly(amidoamine) dendrimer nano material. As verified by in vitro experiments, the target polypeptide has a very hightumor targeting effect and can be widely used as a targeting agent in diagnostic imaging and targeted treatment of tumors.

The invention discloses a preparation method of targeted ferroferric oxide-porphyrin containing composite nanoparticles, and relates to a preparation method of composite nanoparticles. The preparation method disclosed by the invention aims at solving the problems that a photosensitizer is high in accumulation effect within normal tissues and even performs a photochemical reaction under a dark light because a photosensitizer fluorescence signal is low in intensity and low in selective uptake for tumour tissues, existing in photodynamic diagnosis and therapy. The method comprises the following steps: 1, preparing magnetic ferroferric oxide nanoparticles coated by silicon dioxide; 2, preparing a porphyrin compound; 3, preparing a porphyrin compound bound by a silane reagent; 4, preparing a porphyrin-folic acid compound; and 5, preparing the targeted ferroferric oxide-porphyrin containing composite nanoparticles. The preparation method based on the magnetic ferroferric oxide-porphyrin composite nanoparticles and disclosed by the invention integrates magnetofluid thermal therapy, magnetic targeting and photodynamic therapy as a therapy means for tumours. The preparation method disclosed by the invention is used for preparing the targeted ferroferric oxide-porphyrin containing composite nanoparticles.

The invention discloses a targeted polypeptide for vitro and vivo early diagnosis or treatment of lung cancer, belonging to the medicine technical field. The polypeptide is dodecapeptide. The invention also discloses the application of the targeted polypeptide. The targeted polypeptide is applied to a carrier of the targeted therapy of the lung cancer or the preparation of anti-cancer drugs, or used as the medicine of early period and the middle period diagnosis of the lung cancer. The polypeptide provided by the invention is small micro molecule antibody and has smaller antibody molecular weight and strong penetrating power, is easy to reach tumor tissues and can be more sensitive to diagnose the tumor apart from having the advantages of the traditional antibody medicine, thus being in favor of the early diagnosis of the tumor. The polypeptide has good targeted function of the tumor, is suitable for the targeted treatment or the carrier of the targeted treatment and has wide application prospect.

The invention discloses a YAP1 gene which can be used as a molecular marker for early diagnosis of Alzheimer's disease. The QPCR (quantitative polymerase chain reaction) experiment proves that compared with common people, the YAP1 gene expression in the blood of an Alzheimer's disease patient is obviously enhanced. The RNA (ribonucleic acid) interfering experiment proves that the YAP1 can influence the Abeta mediated neurotoxicity action. According to the research results, a drug capable of inhibiting YAP1 gene expression or inhibiting YAP1 gene expression product functions can be developed, thereby implementing clinical prevention and treatment of Alzheimer's disease.

The invention discloses NFIC gene capable of serving as a molecular marker for early diagnosis of pituitary adenomas. Experiments of the invention prove that NFIC gene has significantly improved expression in pituitary adenomas tissues when compared to normal pituitary tissues; RNA interference experiments prove that NFIC can affect the proliferation of pituitary adenomas cells. According to the study results of the invention, it is possible to develop drugs capable of inhibiting NFIC gene expression, thus preventing and treating pituitary adenomas clinically.

The invention aims to provide a method for analyzing proteome in a biological sample. The method can detect unique proteome generated by cancer cells through blood or body fluid in an early stage of tumors; and the method can diagnose cancers more sensitively and more early so as to make early diagnosis and treatment of the cancers possible.

The invention relates to a swine flu virus real-time fluorescent RT-PCR isotyping kit, in particular to a kit for performing isotyping of swine flu viruses by using a one-step method real-time reverse transcription-polymerase chain reaction (RT-PCR) technique. The kit has high sensitivity and specificity. Through the isotyping of the swine flu viruses in respiratory tract specimens and serum and lung tissue samples and other samples by using the kit of the invention, the early-period quick diagnosis of the swine flu viruses is realized, and the trend of the swine flu viruses can be monitored.

The invention belongs to the field of animal disease diagnosis, and particularly relates to a marker GP50 for coenuriasis, as well as a coenuriasis diagnosing kit for diagnosing coenuriasis. According to a coenuriasis indirect ELISA diagnosing method, the sensibility reaches 95%, and the specificity reaches 92.6%. Monitoring of a serum antibody of a goat artificially infected with taenia multiceps discovers that the GP50 antibody values in the whole detection period after infection are all positive. Therefore, the GP50 recombinant protein can be used as the coenuriasis marker, and is used for diagnosing coenuriasis. According to the coenuriasis indirect ELISA diagnosing kit, the coenuriasis can be quickly, sensitively and specifically used for diagnosing coenuriasis, and a foundation is laid for early diagnosis and the treatment effect evaluation of coenuriasis infection.

The invention provides a probe combination for detecting circulating tumor DNA of human thyroid cancer and a capturing and sequencing system thereof. The probe combination comprises a thyroid cancer driving gene exon sequence and a hot spot mutation region sequence. The capturing and sequencing system comprises the probe combination, a hybridizing system, a sequencing device and a circulating freeDNA extracting kit, and performs detection according to the following steps: S1, extracting circulating free DNA from plasma; S2, repairing the tail end of the DNA fragment and adding a connector tothe tail end so as to construct a sequencing library; S3, performing PCR amplification and purification on the library before capturing; S4, hybridizing the amplified sample library with a probe; S5,removing an unbound sequence and eluting a captured sequence; S6, performing PCR amplification and purification again; and S7, performing high-throughput sequencing analysis. According to the capturing and sequencing system, the thyroid cancer can be diagnosed in an early state objectively, sensitively, specifically and stably, and a tumor load is monitored and evaluated so as to achieve timely and pertinent treatment.

The invention discloses application of a non-coding RNA relevant to occurrence and development of laryngeal squamous cell carcinoma. The non-coding RNA is LOC100507599. According to the application, through combination of a high throughput sequencing technology with bioinformation analysis, it is found for the first time that expression of the LOC100507599 in a patient suffering from the laryngealsquamous cell carcinoma is up-regulated, and the conclusion is verified through further QPCR, which indicates that the LOC100507599 can serve as a molecular target to be applied to diagnosis and treatment of the laryngeal squamous cell carcinoma.

The invention discloses a CHKA gene that can function as a molecular marker for early diagnosis of esophageal cancer. Experiments prove that compared with normal esophageal tissues, the CHKA gene in esophageal cancer tissues has significantly increased expression, and RNA interference experiments prove that CHKA can affect proliferation of esophageal cancer cells. According to study results herein, it is possible to develop medicine to inhibit CHKA gene expression so as to clinically prevent and treat the esophageal cancer.

The invention discloses a deep learning-based asynchronous motor fault diagnosis method. The method comprises the following steps of A, building a simulation experiment platform for asynchronous motoroperation; B, carrying out current signal and vibration signal acquisition on a simulated motor fault state; C, extracting internal features of acquired data and carrying out corresponding labellingto complete the construction of a data set; D, building a stack type encoder-based fault diagnosis model and training a network and a classifier in sequence; and E, training a built deep neural network by utilizing the constructed data set, and verifying the fault diagnosis method by combining the simulation experiment platform. According to the method, a deep learning theory is imported to designa system which is capable of correctly, sensitively and effectively diagnosing complicated faults of asynchronous motors, so that the method can solve the problems existing in the fault diagnosis ofthe asynchronous motors and adapt to the requirements of constantly developing electric systems.

The invention discloses applications of TFF2 gene and expression products of TFF2 gene as intracranial aneurysm diagnosis and treatment molecular markers. It can be determined whether a patient is suffered from intracranial aneurysm or the patient possesses the risk of suffering from intracranial aneurysm based on the content of TFF2 gene and the expression products of TFF2 gene in the arterial tissues of the patient. It is found via study on apoptosis conditions of in-vitro cultured vascular smooth muscle cells that interference of TFF2 gene expression is capable of promoting vascular smooth muscle cell apoptosis, so that it is shown by the above results that TFF2 gene and the expression products of TFF2 gene are potential drug targets in treatment of intracranial aneurysm.

The invention discloses a molecular marker-EAPP gene for early diagnosis of the Alzheimer disease. An experimental result shows that the mRNA level of the EAPP gene in blood of the patient suffering from the Alzheimer disease is remarkably lower than that of normal people, so that whether a tested person has the risk of the Alzheimer disease or not or whether the tested person has suffered from the Alzheimer disease or not is judged by determining the expression level of the EAPP gene in the blood of the tested person. The EAPP gene can be used for preparation and application for the patient suffering from the Alzheimer disease or the crowd with the high Alzheimer disease risk so as to be used for treating the Alzheimer disease or preventing the Alzheimer disease. The new diagnosis method is provided for diagnosing the Alzheimer disease clinically and the new candidate medicine is provided for treating the Alzheimer disease.

The invention discloses a gene combination for distinguishing non-invasive and invasive non-functional pituitary adenomas. The gene combination consists of the following genes of INSM1, Jun, JunB, RHOU, RHOB, EZR, LLGL2, SNX33, SPIRE2, MLF1, HSPA2, CDKN1A, ERN1, NR2F2, GAS2, CDK6, SFRP1, EMILIN2, CD9 and SEMA7A. By detecting the expression level of the gene combination, the non-invasive and invasive non-functional pituitary adenomas can be distinguished.

This invention relates to the detection and diagnosis of tuberculosis. More specifically, the invention relates to new biomarkers and combinations thereof that enable the accurate detection and diagnosis of tuberculosis.

The invention provides an EB virus BFRF3-BZLF1 fusion protein, a gene, a vector containing the BZLF1 fusion protein, a host cell, a test strip, a production method and application thereof. The EB virus BFRF3-BZLF1 fusion protein is obtained by connecting the EB virus BFRF3 protein or an EB virus BFRF3 protein fragment with an EB virus BZLF1 protein or EB virus BZLF1 protein fragment through a connecting peptide, and preferably, the EB virus BFRF3-BZLF1 fusion protein has an amino acid sequence shown in SEQ ID NO:1. The EB virus BFRF3-BZLF1 fusion protein can be used as a target antigen for detecting an EB virus, provides a basis for screening and early diagnosing nasopharyngeal carcinoma, infectious mononucleosis and Burkitt lymphoma, and has the advantages of simplicity, rapidness, sensitivity and specificity.

The invention discloses a biomarker related to the occurrence and development of Parkinson's disease. The biomarker is LOC105373557. The invention finds that LOC1053735757 is up-regulated in patientswith Parkinson's disease for the first time. By detecting the expression level of LOC1053735757, whether the subject has Parkinson's disease can be determined. When the level of LOC1035735757 is significantly up-regulated, the subject has Parkinson's disease; and the down-regulation of the expression level of LOC10357575 can change the proliferative activity of Parkinson's disease cells, so as toprovide a molecular treatment means for the patients with Parkinson's disease.

The invention discloses a product for noninvasively diagnosing male osteoporosis. The product can detect the expression level of UTY in the blood of a subject, so that whether the subject is an osteoporosis patient can be judged according to the expression level of the UTY. The method of the product for diagnosing male osteoporosis is simple, the diagnosing can be accomplished by drawing a small amount of blood of the subject, so that the pain of the subject can be reduced; and the product is accurate and reliable in detection result.

The invention discloses application of a THBD gene in Parkinsonism diagnosis. The content of the THBD gene in blood of a Parkinsonism patient is remarkably different from that of a normal person, andthe Parkinsonism patient can be distinguished from a non-Parkinsonism patient according to the difference. The invention further discloses a diagnosis product of Parkinsonism. By means of the diagnosis product, the aim of realizing Parkinsonism diagnosis by detecting the THBD gene in blood can be achieved.

The invention discloses a molecular marker in blood serving as a diagnosis index of respiratory syncytial virus infection. The molecular marker in blood is TYMS. Experiments prove that the content ofTYMS gene and TYMS protein in the blood of people infected with respiratory syncytial virus obviously increases compared with that of normal people. Due to the expression difference between TYMS geneand TYMS protein, the content increase can serve as an index for distinguishing the people infected with respiratory syncytial virus from the non-infected people. Compared with traditional virus antibody detection method and virus antigen detection method, the non-virus index in the blood is adopted for virus detection by the invention, and high-sensitivity detection can be realized.

The invention belongs to the field of medical instruments and particularly relates to a glioma diagnosis and treatment device which comprises a photodynamic irradiation catheter and an implantation catheter mutually matched in use. The photodynamic irradiation catheter comprises an irradiation catheter body, and a photodynamic irradiation optical fiber is arranged in the irradiation catheter body;one end of the photodynamic irradiation optical fiber is positioned on the lower end face of the irradiation catheter body, and the other end of the photodynamic irradiation optical fiber is connected with a photodynamic interface; the irradiation end of the irradiation catheter body is also provided with an imaging component; an illuminating light source is further arranged at the illuminating end of the illuminating catheter body. According to the invention, the split type photodynamic irradiation catheter and the implantation catheter are adopted, the photodynamic irradiation catheter andthe implantation catheter are simple in structure, the device is a microtrauma diagnosis and treatment instrument aiming at tumor recurrence, which can be applied to the head of a patient after gliomaremoval operation for a long time, can be applied repeatedly and minimally invasive, is sensitive, fast and accurate in diagnosis and treatment. The human body implantation part is simple in structure and small in size, can be implanted for a long time, and does not influence the appearance and daily life of the patient.

The invention discloses a molecular marker for diagnosing and treating hysteromyoma. QPCR and Western blot methods prove remarkable difference of expressions of SYBU genes in the hysteromyoma tissue and normal tissues. Moreover, in-vitro cell culture experiments of the invention prove that the expression of the SYBU genes can inhibit the proliferation of hysteromyoma cells while promoting apoptosis, so that the SYBU genes and expression products thereof can be used for preparing a medicine for treating hysteromyoma and are widely and clinically applied.

The invention discloses a CRTAP gene and an expression product thereof capable of serving as a molecular marker for early diagnosis of Alzheimer's disease, namely judging whether a subject suffers from the Alzheimer's disease by detecting the CRTAP gene expression level in blood of the subject. According to the research result of the invention, a medicament capable of inhibiting CRTAP gene expression or inhibiting functions of a CRTAP gene expression product can be researched, thus realizing prevention and treatment of the Alzheimer's disease in clinic.

The invention discloses an MAEA gene and an application of an expression product of the MAEA gene to preparation of a diagnostic product. The diagnostic product can be used for diagnosing myocardial infarction. The risk of myocardial infarction of a testee in the future can be judged or the state of myocardial infarction is confirmed by detecting the level of the MAEA gene and the expression product thereof. The diagnostic product takes peripheral blood of the testee as a detection object, and can achieve noninvasive, rapid, sensitive and accurate diagnostic effects.